Skip to main content

Peer Review reports

From: The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

Original Submission
31 Mar 2016 Submitted Original manuscript
10 Aug 2016 Author responded Author comments - Dara J Lundon
Resubmission - Version 2
10 Aug 2016 Submitted Manuscript version 2
17 Oct 2016 Author responded Author comments - Dara J Lundon
11 Sep 2016 Reviewed Reviewer Report - Yoon Soo Chang
11 Sep 2016 Reviewed Reviewer Report - Yasuyoshi Miyata
Resubmission - Version 3
17 Oct 2016 Submitted Manuscript version 3
8 Dec 2016 Author responded Author comments - Dara J Lundon
8 Nov 2016 Reviewed Reviewer Report - Yoon Soo Chang
1 Nov 2016 Reviewed Reviewer Report - Yasuyoshi Miyata
Resubmission - Version 4
8 Dec 2016 Submitted Manuscript version 4
20 Dec 2016 Author responded Author comments - Dara J Lundon
Resubmission - Version 5
20 Dec 2016 Submitted Manuscript version 5
25 Jan 2017 Author responded Author comments - Dara J Lundon
Resubmission - Version 6
25 Jan 2017 Submitted Manuscript version 6
Publishing
1 Feb 2017 Editorially accepted
1 Mar 2017 Article published 10.1186/s12885-017-3100-4

You can find further information about peer review here.

Back to article page